evidence: When wealthy countries impose price regulations on drugs, they fail to balance the welfare of current and future consumers. Price controls reduce current governments’ and consumers’ health expenditures. As such, many wealthy countries are unwilling to abandon them because doing so means their consumer/taxpayer welfare would fall.[4] In other words, these countries choose to act in their own interest while simultaneously forgetting to consider the health of future citizens, both those in their own country and globally. According to one study, drug price controls reduce "R&D, the flow of new products, firm value, and consumer welfare" for the world.[5] This means today’s price controls will reduce the number of new drugs available to future generations in all countries, including to cure diseases such as heart disease, cancer, stroke, and Alzheimer’s. Conversely, lifting price regulations benefits all countries because it would boost biopharmaceutical revenue, leading to an increase in R&D and the development of new drugs.[6] [...] Price control measures reduce pharmaceutical revenues and, subsequently, the revenue that drives R&D.